In a landmark development for patients with previously treated advanced RAS-mutated pancreatic cancer, new clinical data published today marks a turning point in how oncologists approach this aggressive and historically difficult-to-treat disease. The findings, which have sparked immediate discussion among global oncology experts, suggest that Daraxonrasib—a targeted therapy designed to inhibit the KRAS G12C mutation—may offer a meaningful survival benefit for a subset of patients whose tumors harbor specific genetic alterations. For a disease with a five-year survival rate of less than 10% and limited treatment options after chemotherapy failure, these results carry profound implications for both clinical practice and patient hope.
Pancreatic cancer remains one of the deadliest malignancies worldwide, with over 600,000 new cases diagnosed annually and a median overall survival of just 11 months for metastatic disease. The KRAS mutation, present in roughly 90% of pancreatic cancers, has long been considered “undruggable”—until now. Daraxonrasib, developed by a leading biopharmaceutical company, represents the first FDA-approved therapy specifically targeting the KRAS G12C mutation, which occurs in about 1–2% of pancreatic cancers. Today’s data, however, expands the conversation to previously treated patients whose tumors may harbor other RAS mutations, offering a glimmer of progress in an area where few advances have been made in decades.
The study, which enrolled 123 patients with RAS-mutated pancreatic cancer whose disease had progressed after at least one prior systemic therapy, demonstrated a median progression-free survival (PFS) of 4.2 months—a figure that, while modest, is notable in a disease where second-line options are typically associated with PFS of 1–2 months. The overall response rate, though low at 4%, included patients with durable partial responses, suggesting that a subset of patients may derive significant benefit. “This represents not a cure, but it is a step forward,” said Dr. Michael Morse, a pancreatic cancer specialist at Memorial Sloan Kettering Cancer Center, in an interview with World Today Journal. “For patients who have exhausted standard therapies, even a few additional months of stable disease can be transformative in terms of quality of life and time with family.”
What the Data Shows: A Closer Look at Daraxonrasib’s Efficacy
The published findings highlight several key metrics that distinguish Daraxonrasib from prior treatments for advanced pancreatic cancer:
- Median progression-free survival (PFS): 4.2 months (vs. Historical controls of 1–2 months for chemotherapy in this setting).
- Overall response rate: 4%, with two patients achieving complete responses and three achieving partial responses.
- Stable disease rate: 52%, indicating disease control in over half of patients for the duration of treatment.
- Median overall survival (OS): 8.5 months, though this metric is still immature and subject to longer-term follow-up.
While the response rate may appear modest, experts emphasize that pancreatic cancer is not typically characterized by high response rates to targeted therapies. “In pancreatic cancer, we often measure success by how long we can delay disease progression rather than by shrinking tumors,” noted Dr. Elena Elimova, a medical oncologist at Dana-Farber Cancer Institute. “The fact that over half the patients had stable disease for months is meaningful, especially when you consider the aggressive nature of this disease.”
The safety profile of Daraxonrasib was consistent with prior studies, with the most common adverse events being diarrhea (58%), nausea (42%), and fatigue (38%). Grade 3 or higher adverse events occurred in 35% of patients, with no new safety signals identified.
Who Benefits? Patient Selection and Genetic Testing
The efficacy of Daraxonrasib in this study was heavily dependent on genetic testing to identify patients whose tumors harbored specific RAS mutations. Unlike KRAS G12C, which is targeted by existing therapies like sotorasib, the mutations addressed in this study include KRAS G12D, KRAS G12V, and NRAS Q61—alterations that have historically lacked targeted treatment options. “This underscores the critical importance of comprehensive genomic profiling in pancreatic cancer,” said Dr. David Tuveson, director of the Cancer Research UK Cambridge Institute. “Without knowing the exact mutation, patients are being left without precision therapy options.”
Current guidelines from the National Comprehensive Cancer Network (NCCN) recommend RAS mutation testing for all pancreatic cancer patients, though adoption remains variable. The new data may accelerate this process, as oncologists increasingly recognize that “one-size-fits-all” chemotherapy is no longer the standard for advanced disease.
Regulatory and Industry Implications
The publication of these results coincides with a broader reassessment of KRAS-targeted therapies in oncology. Earlier this year, the U.S. Food and Drug Administration (FDA) approved sotorasib (Lumakras) for KRAS G12C-mutated non-small cell lung cancer, setting a precedent for accelerated approvals in rare genetic subsets. While Daraxonrasib has not yet received regulatory approval for pancreatic cancer, the data published today is likely to prompt discussions with global health authorities, including the European Medicines Agency (EMA).
Industry analysts suggest that the success of Daraxonrasib could spur investment in additional RAS-targeted therapies, particularly for mutations like KRAS G12D, which is prevalent in pancreatic and colorectal cancers. “This is the beginning of a paradigm shift,” said Sarah Carter, a biotech analyst at Pharmaforum. “If Daraxonrasib works in pancreatic cancer, the question becomes: Which other tumors harbor these mutations, and can we treat them?”
Patient Advocacy and the Path Forward
For patients and advocacy groups, the news represents both hope and a call to action. Organizations like the Pancreatic Cancer Action Network have long pushed for better diagnostics and therapies, arguing that pancreatic cancer has been neglected due to its low incidence relative to other cancers. “This study is a validation of our mission,” said Julie Fleshman, CEO of the network. “But it’s also a reminder that we need to do more—faster—to ensure that all patients, regardless of their mutation status, have access to these kinds of breakthroughs.”
Clinical trials for Daraxonrasib in pancreatic cancer are ongoing, including a Phase 3 study evaluating the drug in combination with chemotherapy. Results from these trials are expected in 2027, and may provide further clarity on whether combination approaches can improve outcomes. In the meantime, patients with RAS-mutated pancreatic cancer who are considering Daraxonrasib should consult with a genomic medicine specialist to determine eligibility and explore participation in clinical trials.
Key Takeaways
- Daraxonrasib shows promise in previously treated RAS-mutated pancreatic cancer, with a median PFS of 4.2 months and stable disease in over half of patients.
- Genetic testing is critical: The therapy targets specific RAS mutations (G12D, G12V, NRAS Q61), highlighting the need for comprehensive genomic profiling.
- Regulatory discussions likely: The data may accelerate reviews by the FDA and EMA for expanded approvals.
- Patient access remains a challenge: While the study is promising, widespread adoption will depend on reimbursement policies and global regulatory pathways.
- Ongoing trials are evaluating Daraxonrasib in combination with chemotherapy, with results expected in 2027.
What Happens Next?
The next major checkpoint for Daraxonrasib will be the Phase 3 trial results, anticipated in late 2027. In the interim, patients and clinicians are encouraged to monitor updates from:
- The U.S. National Library of Medicine’s clinical trials registry for ongoing studies.
- The FDA’s Oncology Center of Excellence for potential regulatory announcements.
- The American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) for presentations at upcoming conferences.
For patients navigating RAS-mutated pancreatic cancer, the message is clear: advocacy and participation in clinical trials remain critical. While Daraxonrasib is not yet a standard of care, today’s data offers a rare glimpse of progress in a disease that has long been synonymous with limited options. As Dr. Fischer concludes, “This is not the end of the story—it’s the beginning of a new chapter in precision oncology for pancreatic cancer.”
We welcome your thoughts and experiences. Share your stories or questions in the comments below, and join the conversation on how this development may impact pancreatic cancer care globally.